Tian Zhang, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Grants

Publications

Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol, February 12, 2021. https://doi.org/10.1038/s41565-021-00864-w.

PMID
33580223
Full Text

Hwang, Joyce K., Neeraj Agarwal, James Brugarolas, and Tian Zhang. “Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.” Clin Cancer Res 27, no. 1 (January 1, 2021): 5–7. https://doi.org/10.1158/1078-0432.CCR-20-3506.

PMID
33106290
Full Text

Nelson, A. A., R. J. Cronk, E. A. Lemke, A. Szabo, A. R. Khaki, L. N. Diamantopoulos, P. Grivas, et al. “Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.” Bladder Cancer 7, no. 1 (January 1, 2021): 33–42. https://doi.org/10.3233/BLC-200377.

Full Text

Lin, Chia-Chi, Elena Garralda, Patrick Schöffski, David Hong, Lillian Siu, Miguel Martin, Michela Maur, et al. “387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies.” In Journal for Immunotherapy of Cancer, 8:A412–A412. BMJ, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0387.

Full Text

Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.

PMID
33115529
Full Text

Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.

PMID
32757302
Full Text

Wilson, Lauren E., Lisa Spees, Jessica Pritchard, Melissa A. Greiner, Charles D. Scales, Chris Baggett, Deborah Kaye, et al. “Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Msaouel, P., A. O. Siefker-Radtke, R. Sweis, S. Mao, J. E. Rosenberg, U. N. Vaishampayan, A Rezazadeh Kalebasty, et al. “705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).” In Annals of Oncology, 31:S556–S556. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.777.

Full Text

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID
32392161
Full Text

Pages